Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

bluebird bio Q4 Sales $7.80M May Not Be Comparable To $16.68M Estimate

Author: Benzinga Newsdesk | March 26, 2024 07:06am
bluebird bio (NASDAQ:BLUE) reported quarterly sales of $7.80 million which missed the analyst consensus estimate of $16.68 million by 53.24 percent. This is a 7.70K percent increase over sales of $100.00 thousand the same period last year.

Posted In: BLUE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist